Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
18F-Fluorodeoxyglucose Uptake in PDGFRA-Mutant Gastrointestinal Stromal Tumors.
Nigro MC, Marchetti A, Fumagalli ER, De Luca I, Bertuzzi AF, Grimaudo MS, Grignani G, D'Ambrosio L, Merlini A, Badalamenti G, Incorvaia L, Dimino A, Gasperoni S, Vincenzi B, Fanti S, Di Federico A, Campana D, Pantaleo MA, Nannini M; Tumori Rari Bologna. Nigro MC, et al. Among authors: merlini a. JAMA Netw Open. 2025 Jan 2;8(1):e2456058. doi: 10.1001/jamanetworkopen.2024.56058. JAMA Netw Open. 2025. PMID: 39853981
Ecteinascidin synthetic analogues: a new class of selective inhibitors of transcription, exerting immunogenic cell death in refractory malignant pleural mesothelioma.
Salaroglio IC, Aviles P, Kopecka J, Merlini A, Napoli F, Righi L, Novello S, Sullivan H, Cuevas C, Scagliotti GV, Riganti C. Salaroglio IC, et al. Among authors: merlini a. J Exp Clin Cancer Res. 2024 Dec 21;43(1):327. doi: 10.1186/s13046-024-03253-y. J Exp Clin Cancer Res. 2024. PMID: 39709435 Free PMC article.
Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA).
Passiglia F, Listì A, Bironzo P, Merlini A, Benso F, Napoli F, Barbu FA, Zambelli V, Tabbò F, Reale ML, Sini C, Roca E, Taveggia PA, Simionato F, Buffoni L, Mazilu L, Barbieri V, Pignataro D, Araujo A, Paz-Ares L, Felip E, Secen N, Comanescu A, Ramizi KM, Bettini AC, Scotti V, Linardou H, Mohorcic K, Meoni G, Giannarelli D, Volante M, Malapelle U, Vallone S, Scagliotti G, Righi L, Novello S. Passiglia F, et al. Among authors: merlini a. J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02529-2. doi: 10.1016/j.jtho.2024.12.010. Online ahead of print. J Thorac Oncol. 2024. PMID: 39694416 Free article.
Active surveillance in patients with extra-abdominal desmoid-type fibromatosis: a pooled analysis of three prospective observational studies.
Colombo C, Hakkesteegt S, Le Cesne A, Barretta F, Blay JY, Grünhagen DJ, Penel N, Lam L, Fiore M, Palassini E, Grignani G, Tolomeo F, Collini P, Merlini A, Perrone F, Stacchiotti S, Verhoef C, Bonvalot S, Gronchi A. Colombo C, et al. Among authors: merlini a. Clin Cancer Res. 2024 Dec 2. doi: 10.1158/1078-0432.CCR-24-2340. Online ahead of print. Clin Cancer Res. 2024. PMID: 39620931
Three-dimensional dynamics of mesothelin-targeted CAR.CIK lymphocytes against ovarian cancer peritoneal carcinomatosis.
Galvagno F, Leuci V, Massa A, Donini C, Rotolo R, Capellero S, Proment A, Vitali L, Lombardi AM, Tuninetti V, D'Ambrosio L, Merlini A, Vigna E, Valabrega G, Primo L, Puliafito A, Sangiolo D. Galvagno F, et al. Among authors: merlini a. Cancer Immunol Immunother. 2024 Nov 2;74(1):6. doi: 10.1007/s00262-024-03860-w. Cancer Immunol Immunother. 2024. PMID: 39487859 Free PMC article.
From Cancer to Immune Organoids: Innovative Preclinical Models to Dissect the Crosstalk between Cancer Cells and the Tumor Microenvironment.
Picca F, Giannotta C, Tao J, Giordanengo L, Munir HMW, Botta V, Merlini A, Mogavero A, Garbo E, Poletto S, Bironzo P, Doronzo G, Novello S, Taulli R, Bersani F. Picca F, et al. Among authors: merlini a. Int J Mol Sci. 2024 Oct 9;25(19):10823. doi: 10.3390/ijms251910823. Int J Mol Sci. 2024. PMID: 39409152 Free PMC article. Review.
GDF-15 Predicts Epithelioid Hemangioendothelioma Aggressiveness and Is Downregulated by Sirolimus through ATF4/ATF5 Suppression.
Stacchiotti S, Martini S, Pasquali S, Frezza AM, Beretta A, Percio S, Lecchi M, Tortoreto M, Barisella M, Collini P, Dagrada GP, Merlini A, Huang PH, Jenks A, Jones RL, Tap WD, Ingrosso M, Morosi C, Brich S, Giani C, Verderio P, Casali PG, Leonard H, Gronchi A, Zuco V, Zaffaroni N. Stacchiotti S, et al. Among authors: merlini a. Clin Cancer Res. 2024 Nov 15;30(22):5122-5137. doi: 10.1158/1078-0432.CCR-23-3991. Clin Cancer Res. 2024. PMID: 39283723 Free PMC article.
Targeting the EphA2 pathway: could it be the way for bone sarcomas?
Giordano G, Tucciarello C, Merlini A, Cutrupi S, Pignochino Y. Giordano G, et al. Among authors: merlini a. Cell Commun Signal. 2024 Sep 9;22(1):433. doi: 10.1186/s12964-024-01811-7. Cell Commun Signal. 2024. PMID: 39252029 Free PMC article. Review.
Correction: TFEB controls sensitivity to chemotherapy and immuno-killing in non-small cell lung cancer.
Akman M, Monteleone C, Doronzo G, Godel M, Napoli F, Merlini A, Campani V, Nele V, Balmas E, Chontorotzea T, Fontana S, Digiovanni S, Alice Barbu F, Astanina E, Jafari N, Chiara Salaroglio I, Kopecka J, De Rosa G, Mohr T, Bertero A, Righi L, Novello S, Vittorio Scagliotti G, Bussolino F, Riganti C. Akman M, et al. Among authors: merlini a. J Exp Clin Cancer Res. 2024 Aug 29;43(1):244. doi: 10.1186/s13046-024-03170-0. J Exp Clin Cancer Res. 2024. PMID: 39198838 Free PMC article. No abstract available.
98 results